Brokerage Firm Rating Update on Boston Scientific Corporation (BSX)

Boston Scientific Corporation (BSX) : The consensus on Boston Scientific Corporation (BSX) based on 20 analyst recommendation on the company stock is 1.63, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 12 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 3 analyst believes that the stock is a Buy, which can produce decent returns in the future. 5 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Boston Scientific Corporation (BSX) stock is expected to deviate a maximum of $2.99 from the average target price of $26.08 for the short term period. 18 Street Experts have initiated coverage on the stock with the most promising target being $30 and the most muted being $20.


For the current week, the company shares have a recommendation consensus of Buy. Also, Equity analysts at the Brokerage firm Argus Research upgrades its rating on Boston Scientific Corporation (NYSE:BSX). The rating major has initiated the coverage with buy rating on the shares. Earlier, the shares were rated a Hold by the brokerage firm. The Analysts at Argus Research announces a current price target of $33 per share. The rating by the firm was issued on September 1, 2016.

Boston Scientific Corporation (NYSE:BSX): The stock opened at $24.28 and touched an intraday high of $24.45 on Wednesday. During the day, the stock corrected to an intraday low of $24.25, however, the bulls stepped in and pushed the price higher to close in the green at $24.41 with a gain of 0.33% for the day. The total traded volume for the day was 6,155,121. The stock had closed at $24.33 in the previous trading session.

Boston Scientific Corporation develops, manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology, which includes Drug-Eluting Coronary Stent Systems, Intravascular Imaging devised and Coronary Technology products, such as guide wires, guide catheters, and balloon catheters, among others; Peripheral Interventions (PI), which include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM), which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP), which include steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories; Endoscopy, which includes Spyglass System, WallFlex Colonic Stents, Resolution Clip, and Expect Aspiration Needle, among others; Urology and Womens Health, and Neuromodulation.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.